secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001654954-24-011975
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27
--------------------------------------------------------------------------------

- Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.
- 73% reduction in risk of death (HR 0.27, 95% CI [0.12-0.64], Wald p=0.0027) in that subgroup.
- Data presented at ESMO 2024 support confirmatory Registration Study (212 patients) with FDA go-ahead.
- Target population: newly diagnosed locally advanced head & neck cancer, no lymph node involvement, low PD-L1.
- Phase 3 study subset (n=79) deemed low risk for recurrence per NCCN guidelines, not recommended chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495424011975/0001654954-24-011975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495424011975/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-011975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer